Patient Profiles

Patient Profiles

LYFNUA®▼ (gefapixant)
Prescribing Information [External link]

LYFNUA is indicated in adults for the treatment of refractory and unexplained chronic cough¹

LYFNUA is available by private prescription only and is not available via the NHS

As a treatment indicated for refractory or unexplained chronic cough, LYFNUA®▼ (gefapixant) helps address an unmet medical need^1,2

Patients with chronic cough, including refractory or unexplained chronic cough, may experience:

• A nonproductive cough^3,4
• Dizziness, headaches, or exhaustion^5-8
• Speech interruptions^5-8
• Anxiousness, depressive feelings, or sleep disruptions^5,6,9
• Stress urinary incontinence^5,6
• Multiple meetings with general practitioners and specialists^3,10
• Multiple tests or treatments in an effort to reduce their cough^3,10
• Disruption in social and recreational activities^5,6

• Gemma
• Tae-Hyun

LYFNUA may help Gemma cough less and feel more comfortable going out¹

Background

• 63-year-old never-smoker with a history of chronic cough for 10 years
• Previously diagnosed and adequately treated for mild asthma
• No other potential causes of her cough were identified, despite a thorough evaluation
• Experienced nightly bouts of coughing that kept her from having a restful sleep

Diagnosis and treatment

• Refractory chronic cough: cough associated with a comorbid condition (eg, asthma, GERD, or UACS, post nasal drip) that persisted despite adequate treatment of the comorbid condition¹
• Gemma was prescribed LYFNUA 45 mg twice daily and instructed to continue with her asthma regimen¹

This is a fictional patient

LYFNUA may help Tae-Hyun focus on more than just chronic cough

Background

• 55-year-old never-smoker with persistent dry cough for 2 years
• Cough impacted social life and singing group
• Experienced uncontrollable coughing while singing or talking
• Thorough evaluation did not identify any cough-associated conditions

Diagnosis and treatment

• Refractory or Unexplained Chronic Cough: persistent cough despite thorough investigation and/or treatment according to published practice guidelines¹
• Tae-Hyun was prescribed LYFNUA 45 mg twice daily¹

This is a fictional patient

References

1. LYFNUA Summary of Product Characteristics.
2. Muccino DR, Green S. Pulm Pharmacol Ther. 2019;56:75-78.
3. Satia I et al. Clin Med (Lond). 2016;16(Suppl 6):S92-S97.
4. Gibson P et al. Chest. 2016;149:27-44.
5. French CL et al. Arch Intern Med. 1998;158:1657-1661.
6. Kuzniar TJ et al. Mayo Clin Proc. 2007;82:56-60.
7. Irwin RS et al. Chest. 2020;158:2058-2073.
8. Chronic Cough: Symptoms and Causes. Accessed May 31, 2024. https://www.mayoclinic.org/diseases-conditions/chronic-cough/symptoms-causes/syc-20351575
9. Dicpinigaitis PV et al. Chest. 2006;130:1839-1843.
10. Zeiger RS et al. J Allergy Clin Immunol Pract. 2021;9:1624-1637.e10.

Supporting documentation

LYFNUA®▼ (gefapixant)
Prescribing Information (Great Britain)

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website